Abstract
Mitogen-activated protein kinase p38 is a serine/threonine kinase originally isolated from lipopolysaccharide (LPS) stimulated monocytes. There are four isoforms p38α, p38β, p38γ, and p38δ. The most thoroughly studied isoform is p38α, whose activation has been observed in many hematopoietic and nonhematopoietic cell types upon appropriate stimuli. Subsequently, p38α kinase has been shown to be involved in the biosynthesis of TNFα and IL-1β at the translational and transcriptional level. MAP kinase p38agr; represents a point of convergence for multiple signaling processes that are activated in inflammation and thus a key potential target for the modulation of cytokine production. The discovery and publication of p38α and the pyridinyl-imidazole inhibitor initiated a huge effort by many companies to develop p38α inhibitors as potential treatment for inflammatory diseases. Herein we provide a brief overview of recent reported clinical results for AMG 548, BIRB 796, VX 702, SCIO 469, and SCIO 323. However, our focus will be on the binding modes of these inhibitors and other p38 inhibitors in the recent literature.
Keywords: p38 inhibitors, map kinase, tnfα, il-1β, dgf in, dgf out, amg 548, birb 796, scio 469
Current Medicinal Chemistry
Title: MAP Kinase p38Inhibitors: Clinical Results and an Intimate Look at Their Interactions with p38α Protein
Volume: 12 Issue: 25
Author(s): Matthew R. Lee and Celia Dominguez
Affiliation:
Keywords: p38 inhibitors, map kinase, tnfα, il-1β, dgf in, dgf out, amg 548, birb 796, scio 469
Abstract: Mitogen-activated protein kinase p38 is a serine/threonine kinase originally isolated from lipopolysaccharide (LPS) stimulated monocytes. There are four isoforms p38α, p38β, p38γ, and p38δ. The most thoroughly studied isoform is p38α, whose activation has been observed in many hematopoietic and nonhematopoietic cell types upon appropriate stimuli. Subsequently, p38α kinase has been shown to be involved in the biosynthesis of TNFα and IL-1β at the translational and transcriptional level. MAP kinase p38agr; represents a point of convergence for multiple signaling processes that are activated in inflammation and thus a key potential target for the modulation of cytokine production. The discovery and publication of p38α and the pyridinyl-imidazole inhibitor initiated a huge effort by many companies to develop p38α inhibitors as potential treatment for inflammatory diseases. Herein we provide a brief overview of recent reported clinical results for AMG 548, BIRB 796, VX 702, SCIO 469, and SCIO 323. However, our focus will be on the binding modes of these inhibitors and other p38 inhibitors in the recent literature.
Export Options
About this article
Cite this article as:
Lee R. Matthew and Dominguez Celia, MAP Kinase p38Inhibitors: Clinical Results and an Intimate Look at Their Interactions with p38α Protein, Current Medicinal Chemistry 2005; 12 (25) . https://dx.doi.org/10.2174/092986705774462914
DOI https://dx.doi.org/10.2174/092986705774462914 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
T-Cell-Mediated Signalling in Immune, Inflammatory and Angiogenic Processes: The Cascade of Events Leading to Inflammatory Diseases
Current Drug Targets - Inflammation & Allergy RNAi Screening for the Discovery of Novel Modulators of Human Disease
Current Pharmaceutical Biotechnology Carbonic Anhydrase Inhibitors and the Management of Cancer
Current Topics in Medicinal Chemistry A New Application Route of Nitrofurantoin: Preparation and Characterization of Novel Transdermal Formulations
Current Drug Delivery Energy Balance and Carcinogenesis: Underlying Pathways and Targets for Intervention
Current Cancer Drug Targets Anti-Diabetic Effects of Isolated Lipids from Natural Sources through Modulation of Angiogenesis
Current Molecular Pharmacology Cognitive Identity in Schizophrenia: Vision, Space, and Body Perception from Prodrome to Syndrome
Current Psychiatry Reviews C. elegans as a Genetic Model System to Identify Parkinson's Disease- Associated Therapeutic Targets
CNS & Neurological Disorders - Drug Targets Mechanisms of Chondrocyte Survival and Matrix Synthesis During Hypoxia
Current Rheumatology Reviews Role of Nitric Oxide in the Modulation of Angiogenesis
Current Pharmaceutical Design The New Immunosuppression: Intervention at the Dendritic Cell-T-Cell Interface
Current Drug Targets - Immune, Endocrine & Metabolic Disorders Mesothelioma - Epidemiology and Management
Current Respiratory Medicine Reviews Autocrine and Paracrine Secretion of Vascular Endothelial Growth Factor in the Pre-Hypoxic Diabetic Retina
Current Diabetes Reviews Suicidal emperipolesis: a process leading to cell-in-cell structures, T cell clearance and immune homeostasis.
Current Molecular Medicine Role of Differential Signaling Pathways and Oxidative Stress in Diabetic Cardiomyopathy
Current Cardiology Reviews Non-Steroidal Targets in the Diagnosis and Treatment of Endometriosis
Current Medicinal Chemistry The Immune Function of Ly6Chi Inflammatory Monocytes During Infection and Inflammation
Current Molecular Medicine The Use of Cytokines and Chemokines in the Cancer Immunotherapy
Recent Patents on Anti-Cancer Drug Discovery Chronic Inflammatory-Modulating Potential of <i>Cassia auriculata</i> with Proinflammatory Cytokine IL-1beta and Its Anticancer Effect on Lung Cancer Cell Line
Anti-Cancer Agents in Medicinal Chemistry Novel Therapeutic Agents for Hyperuricemia in Patients with Gout
Current Drug Therapy